AI assistant
NovoCure Ltd — Director's Dealing 2024
Jun 6, 2024
31949_dirs_2024-06-06_65b1666e-2552-4517-94f9-c9b45c28d277.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2024-06-04
Reporting Person: VERNON W ANTHONY (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-04 | Ordinary Shares | S | 964.00 | $23.893 | Disposed | 164833.00 | Direct |
| 2024-06-05 | Restricted Stock Units | A | 4053.00 | $0.00 | Acquired | 169850.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-05 | Stock Option (Right to Buy) | $23.13 | A | 6229.00 | Acquired | 2034-06-04 | Ordinary Shares (6229.00) | Direct |
Footnotes
F1: This transaction was executed in multiple trades at prices ranging from $23.78 USD to $24.00 USD; the price reported above reflects the weighted average sale price.
F2: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.
F3: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders.